EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes

View source ↗

Summary

EMA confirms recommendations to minimize risk of ketoacidosis associated with SGLT2 inhibitors used for diabetes management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)